Form 4: Castle Biosciences CEO Derek Maetzold Sells Shares Under 10b5-1 Plan

Castle Biosciences CEO Derek Maetzold executed sales of common stock on May 6, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On May 6, 2024, Derek J Maetzold, the President and CEO of Castle Biosciences, Inc., sold shares of common stock at a price of $24.72.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2023.
• Maetzold sold 2,368 shares directly and also disposed of shares held in various trusts for the benefit of his family members.
• The transactions resulted in changes to the beneficial ownership of common stock held directly and indirectly by Maetzold and related trusts.
• Following the transactions, Maetzold directly owns 62,629 shares.
• Maetzold also has indirect ownership through several trusts, including The Maetzold Descendants 2020 Trust (84,906 shares), Derek Maetzold 2020 Irrevocable Trust (73,803 shares), The Maetzold 2018 Remainder Trusts (9,299, 9,297, 9,297, 9,297 shares each), and DJM Grantor Retained Annuity Trust No. 5 (149,000 shares).

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock sales by an executive. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.

Industry Context

This filing is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information.

Stakeholder Impact

• The stock sale could have a minor impact on shareholder sentiment, but the existence of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates